Immuneering

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Immuneering and other ETFs, options, and stocks.

About IMRX

Immuneering Corp. operates as a clinical-stage oncology company, which engages in developing medicines for cancer patients. Its pipeline of drug candidates focuses on treating aspects of disease that have eluded conventional approaches, including cancer cachexia and metastasis.

CEO

Benjamin J. Zeskind

CEOBenjamin J. Zeskind

Employees

Employees66

Headquarters

Cambridge, Massachusetts

HeadquartersCambridge, Massachusetts

Founded

2008

Founded2008

Employees

Employees66

IMRX Key Statistics

Market cap

51.64M

Market cap51.64M

Price-Earnings ratio

-0.71

Price-Earnings ratio-0.71

Dividend yield

—

Dividend yield—

Average volume

96.97K

Average volume96.97K

High today

$1.49

High today$1.49

Low today

$1.43

Low today$1.43

Open price

$1.47

Open price$1.47

Volume

47.22K

Volume47.22K

52 Week high

$3.83

52 Week high$3.83

52 Week low

$1.00

52 Week low$1.00

Immuneering

Why Robinhood?

Immuneering Corp. operates as a clinical-stage oncology company, which engages in developing medicines for cancer patients. Its pipeline of drug candidates focuses on treating aspects of disease that have eluded conventional approaches, including cancer cachexia and metastasis. Show more

IMRX Key Statistics

Immuneering Corp. operates as a clinical-stage oncology company, which engages in developing medicines for cancer patients. Its pipeline of drug candidates focuses on treating aspects of disease that have eluded conventional approaches, including cancer cachexia and metastasis.